en · de · es · fr · pt
tb-500-notes.peptides5388.com › Data › Tb-500 Background And Identity — Common Mistakes

Tb-500 Background And Identity — Common Mistakes

By Editorial Desk · published 2026-06-06 · last reviewed 2026-07-27 · Data

The short version of research peptide fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.

TB-500 Background and Identity

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

TB-500 Identity and Naming Background

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white lyophilized powderTypical form for short synthetic peptides
Solubility classFreely soluble in water and aqueous bufferDissolution aided by gentle mixing, not vigorous shaking
Typical storage temperature−20 °C, desiccated−80 °C used for long-term holding
Common analytical methodReverse-phase HPLC with UV detection near 214 nmIdentity confirmed separately by mass spectrometry
Common synonymsThymosin beta-4 fragment; TB4 fragmentNaming varies between suppliers and publications

TB-500 Identity and Molecular Background

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Related pages on this site

Identity and Research Background

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Supporting material

=== Non-invasive magnetic methods === Magnetic methods of neuromodulation are normally non-invasive: no surgery is required to allow a magnetic field to enter the body because the magnetic permeability of tissue is similar to that of air. In other words, magnetic fields penetrate the body very easily. The two main techniques are highly related in that both use changes in magnetic field strength to induce electric fields and ionic currents in the body. There are, however, differences in approach and hardware. In rTMS, the stimulation has a high amplitude (0.5–3 tesla), a low complexity and anatomical specificity is reached through a highly focal magnetic field. In tPEMF, the stimulation has a low amplitude (0.01–500 millitesla), a high complexity and anatomical specificity is reached through the specific frequency content of the signal.

=== 1947–1948 === In January 1947, the AHE was renamed the "Arab Higher Committee", with Amin al-Husayni as its chairman and Jamal al-Husayni as vice-chairman, and expanded to include the four remaining core members plus Hasan Abu Sa'ud, Izhak Darwish al-Husayni, Izzat Darwaza, Rafiq al-Tamimi and Mu'in al-Madi. This restructuring of the AHC to include additional supporters of Amin al-Husayni was seen as a bid to increase his political power. Following the failure of the London Conference, the British referred the question to the UN on 14 February 1947. In April 1947, the Arab Higher Committee repeated Arab and Palestinian demands in the solution for the Question of Palestine:

=== Etymology === Rheumatoid arthritis is derived from the Greek word ῥεύμα-rheuma (nom.), ῥεύματος-rheumatos (gen.) ("flow, current"). The suffix -oid ("resembling") gives the translation as joint inflammation that resembles rheumatic fever. Rhuma, which means watery discharge, might refer to the fact that the joints are swollen or that the disease may be made worse by wet weather.

During the beginning (acute) phase of inflammation, particularly as a result of bacterial infection, environmental exposure, and some cancers, neutrophils are one of the first responders of inflammatory cells to migrate toward the site of inflammation. They migrate through the blood vessels and then through interstitial space, following chemical signals such as interleukin-8 (IL-8), C5a, fMLP, leukotriene B4, and hydrogen peroxide (H2O2) in a process called chemotaxis. They are the predominant cells in pus, accounting for its whitish-to-yellowish appearance. Neutrophils are recruited to the site of injury within minutes following trauma and are the hallmark of acute inflammation. They not only play a central role in combating infection but also contribute to pain in the acute period by releasing pro-inflammatory cytokines and other mediators that sensitize nociceptors, leading to heightened pain perception. However, due to some pathogens being indigestible, they may not be able to resolve certain infections without the assistance of other types of immune cells.

Xavier Bichat introduced the word tissue into the study of anatomy by 1801. He was "the first to propose that tissue is a central element in human anatomy, and he considered organs as collections of often disparate tissues, rather than as entities in themselves". Although he worked without a microscope, Bichat distinguished 21 types of elementary tissues from which the organs of the human body are composed, a number later reduced by other authors. In 2013, the work of de Bono et al introduced the concept of the Functional Tissue Unit (FTU) as a biophysical definition of spatial tissue domains that satisfy both long-range and short range (i.e., local) communication constraints for cellular maintenance and supracellular organization (i.e., architecture). A FTU consists of a cylindrical diffusive field of parenchyma centered around a tube. This central tube conveys long-range flow of a body fluid (e.g., blood, bile, air, urinary ultra-filtrate). It is compelling to draw parallels between the biophysical constraints that act upon a tissue domain and those acting on a protein domain. In this analogy, the FTU’s central tube is akin to the peptide backbone in a protein domain, and the cells in the surrounding diffusive cuff are analogous to interacting amino acid side chains.

Sources: en.wikipedia.org

Supporting material

In response to shifts in federal policy in the transition between the Biden and Trump administrations, Pritzker signed a number of bills codifying federal labor protections into state law: the Illinois Workers' Rights and Safety Act, which preserves regulations defined by the Occupational Safety and Health Act of 1970, the Fair Labor Standards Act of 1938, and the Federal Coal Mine Health and Safety Act of 1969, regardless of any changes at the federal level; an amendment to the Prevailing Wage Act that ensures that workers for federally funded construction projects administered by the state or local governments are paid the Illinois prevailing wage whenever it is higher than the federal rate; and a bill eliminating references to the Equal Pay Act of 1963 that would have tied some provisions to federal programs, so that federal changes will not undermine the state's requirement that employers with 100 or more employees report on wages by employees' gender and race or ethnicity.

Lucas, the youngest Marine to receive the Medal of Honor, who then re-enlisted and became a Captain in the 82nd Senator Dave McCormick (born 1965), Captain who served in the Gulf War Wes Moore, 63rd governor of Maryland Platoon Forward Observer and Member of USA National Bobsled Team Lou Moreira Country music singer Craig Morgan (born 1964) Patrick Murphy, Under Secretary of the Army (born 1973) Actor Noble Craig, Vietnam War R&B singer Lou Rawls Sergeant in B Co 2/505 ABN INF 1956–58 Senator Jack Reed (born 1949) Dennis Richmond, journalist Syracuse University football coach Ben Schwartzwalder General "Henry" Hugh Shelton (Chairman of the Joint Chiefs of Staff from 1997 to 2001) Private John Steele who famously got hung up on a parapet of the church bell tower when jumping into Sainte-Mère-Église during the first hours of D-Day. Senator Strom Thurmond (325th Glider Infantry Regiment in World War II) Actor William Windom Colonel Benjamin H. Vandervoort who led the 2nd Battalion, 505th PIR on D-Day and the 3rd Battalion, 504th PIR during Operation Market Garden. Sergeant Alvin C. York (Medal of Honor recipient), World War I Trae Stewart Spurlock a 2x combat veteran killed by the Casper Police Department James Megellas One of the most decorated veterans of the 82nd

Subclass Nautiloidea: Fundamental ectocochliate cephalopods that provided the source for the Ammonoidea and Coleoidea. Order † Plectronocerida: the ancestral cephalopods from the Cambrian Period Order † Ellesmerocerida (500 to 470 Ma) Order † Endocerida (485 to 430 Ma) Order † Actinocerida (480 to 312 Ma) Order † Discosorida (482 to 392 Ma) Order † Pseudorthocerida (432 to 272 Ma) Order † Tarphycerida (485 to 386 Ma) Order † Oncocerida (478.5 to 324 Ma) Order Nautilida (extant; 410.5 Ma to present) Order † Orthocerida (482.5 to 211.5 Ma) Order † Ascocerida (478 to 412 Ma) Order † Bactritida (418.1 to 260.5 Ma) Subclass † Ammonoidea: ammonites (479 to 66 Ma) Order † Goniatitida (388.5 to 252 Ma) Order † Ceratitida (254 to 200 Ma) Order † Ammonitida (215 to 66 Ma) Subclass Coleoidea (410.0 Ma-Rec) Cohort † Belemnoidea: Belemnites and kin Genus † Jeletzkya Order † Aulacocerida (265 to 183 Ma) Order † Phragmoteuthida (189.6 to 183 Ma) Order † Hematitida (339.4 to 318.1 Ma) Order † Belemnitida (339.4 to 66 Ma) Genus † Belemnoteuthis (189.6 to 183 Ma) Cohort Neocoleoidea Superorder Decapodiformes (also known as Decabrachia or Decembranchiata) Order Spirulida: ram's horn squid Order Sepiida: cuttlefish Order Sepiolida: pygmy, bobtail and bottletail squid Order Idiosepida Order Oegopsida: neritic squid Order Myopsida: coastal squid Order Bathyteuthida Superorder Octopodiformes (also known as Vampyropoda) Family † Trachyteuthididae Order Vampyromorphida: vampire squid Order Octopoda: octopus Superorder † Palaeoteuthomorpha Order † Boletzkyida Other classifications differ, primarily in how the various decapod orders are related, and whether they should be orders or families.

A broad-spectrum chemokine inhibitor (BSCI), also termed chemotide or somatotaxin, is a type of experimental anti-inflammatory drug that inhibits the action of the pro-inflammatory proteins chemokines. Radiolabeling experiments performed by Dr. David Fox, University of Warwick, demonstrated the ability of the BSCI to bind and antagonize the somatostatin receptor 2 (SSTR2). This is a display of functional selectivity at the SSTR2 receptor. Functional selectivity is the effect of one ligand having one agonism when bound to the receptor and another ligand having a different agonism at that same receptor.

A sarcoma is a rare type of cancer that arises from cells of mesenchymal origin, meaning that sarcomas are cancers of connective tissues such as bone, cartilage, muscle, fat, or vascular tissues. Sarcomas are one of five different types of cancer, classified by the cell type from which they originate. While there are five types under this category, sarcomas are most frequently contrasted with carcinomas which are much more common. Sarcomas are quite rare, making up about 1% of all adult cancer diagnoses and 15% of childhood cancer diagnoses. There are many subtypes of sarcoma, which are classified based on the specific tissue and type of cell from which the tumor originates. Common examples of sarcoma include liposarcoma, leiomyosarcoma, and osteosarcoma. Sarcomas are primary connective tissue tumors, meaning that they arise in connective tissues. This is in contrast to secondary (or "metastatic") connective tissue tumors, which occur when a cancer from elsewhere in the body (such as the lungs, breast tissue or prostate) spreads to the connective tissue. The word sarcoma is derived from the Greek σάρκωμα sarkōma 'fleshy excrescence or substance', itself from σάρξ sarx meaning 'flesh'.

Sources: en.wikipedia.org

Notes from published material

Eighteen isotopes and four nuclear isomers are known for einsteinium, with mass numbers 240–257. All are radioactive; the most stable one, 252Es, has half-life 471.7 days. The next most stable isotopes are 254Es (half-life 275.7 days), 255Es (39.8 days), and 253Es (20.47 days). All the other isotopes have half-lives shorter than 40 hours, most shorter than 30 minutes. Of the five isomers, the most stable is 254mEs with a half-life of 39.3 hours.

=== „Dein Name“ (2015) === Considering that Kermani described this novel in his Frankfurt lectures on poetics as a failed attempt to capture the specific shock of death in a conventional literary form, we have to read this assessment against the backdrop of his extensive work on his major novel Dein Name [Your Name], which was originally conceived as a book of the dead and is committed to a different kind of remembrance of the dead. With its 1,229 densely printed pages, Dein Name is Kermani's longest work. Classified by many critics as his magnum opus, it represents one of the most original works of autofiction in contemporary literature. The text is narrated by a character named Navid Kermani, who shares many, but not all, biographical details with the author. The narrative combines the styles of, among other genres, a diary, a relationship and family novel, a travel reportage, an internet blog, an epistolary or text messages novel, a poetological and scholarly treatise, a political essay, and—presented as its core—obituary-like commemorative texts. These short texts are dedicated to individuals almost all of whom were close to the author and whom he lost during the period between June 8, 2006, and June 11, 2011, while he was working on this novel. On a second narrative level, the novel tells the story of its own fashioning, not only in terms of poetics and the writing process, but in terms of the author-character’s entire life.

== See also == Clinical Laboratory Improvement Amendments (CLIA) GxP Good clinical practice Good Automated Manufacturing Practice Joint Committee for Traceability in Laboratory Medicine International Laboratory Accreditation Cooperation International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Drug development ISO 15189 Verification and Validation

1,1'-Carbonyldiimidazole (CDI) is an organic compound with the molecular formula (C3H3N2)2CO. It is a white crystalline solid. It is often used for the coupling of amino acids for peptide synthesis and as a reagent in organic synthesis.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.

Is TB-500 identical to thymosin beta-4?

Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.

Is TB-500 an approved medicine?

No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

Network